Chimerix, Inc. (CMRX)'s Brincidofovir (CMX001) Selected For Two Oral Presentations At The 2014 BMT Tandem Meetings
2/24/2014 9:00:22 AM
DURHAM, N.C., Feb. 21, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced two oral presentations related to its broad-spectrum investigational antiviral, brincidofovir (CMX001), at the BMT Tandem Meetings being held February 26 – March 2, 2014 in Grapevine, Texas. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT).
Help employers find you! Check out all the jobs and post your resume.
comments powered by